Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 273

1.

Effects of cessation of cigarette smoking on eicosanoid biomarkers of inflammation and oxidative damage.

McElroy JP, Carmella SG, Heskin AK, Tang MK, Murphy SE, Reisinger SA, Jensen JA, Hatsukami DK, Hecht SS, Shields PG.

PLoS One. 2019 Jun 28;14(6):e0218386. doi: 10.1371/journal.pone.0218386. eCollection 2019.

2.

Betel Nnut (areca) and Smokeless Tobacco Use in Myanmar.

Papke RL, Bhattacharyya I, Hatsukami DK, Moe I, Glatman S.

Subst Use Misuse. 2019 Jun 20:1-10. doi: 10.1080/10826084.2019.1624774. [Epub ahead of print]

PMID:
31220988
3.

Strategies to Reduce Illicit Trade of Regular Nicotine Tobacco Products After Introduction of a Low-Nicotine Tobacco Product Standard.

Ribisl KM, Hatsukami DK, Huang J, Williams RS, Donny EC.

Am J Public Health. 2019 Jul;109(7):1007-1014. doi: 10.2105/AJPH.2019.305067.

PMID:
31166743
4.

Effects of immediate versus gradual nicotine reduction in cigarettes on biomarkers of biological effects.

Hatsukami DK, Luo X, Heskin AK, Tang MK, Carmella SG, Jensen J, Robinson JD, Vandrey R, Drobes DJ, Strasser AA, al'Absi M, Leischow S, Cinciripini PM, Koopmeiners J, Ikuemonisan J, Benowitz NL, Donny EC, Hecht SS.

Addiction. 2019 May 29. doi: 10.1111/add.14695. [Epub ahead of print]

PMID:
31140663
5.

Longitudinal stability in cigarette smokers of urinary eicosanoid biomarkers of oxidative damage and inflammation.

Carmella SG, Heskin AK, Tang MK, Jensen J, Luo X, Le CT, Murphy SE, Benowitz NL, McClernon FJ, Vandrey R, Allen SS, Denlinger-Apte R, Cinciripini PM, Strasser AA, al'Absi M, Robinson JD, Donny EC, Hatsukami DK, Hecht SS.

PLoS One. 2019 Apr 25;14(4):e0215853. doi: 10.1371/journal.pone.0215853. eCollection 2019.

6.

Smokeless tobacco control in 180 countries across the globe: call to action for full implementation of WHO FCTC measures.

Mehrotra R, Yadav A, Sinha DN, Parascandola M, John RM, Ayo-Yusuf O, Nargis N, Hatsukami DK, Warnakulasuriya S, Straif K, Siddiqi K, Gupta PC.

Lancet Oncol. 2019 Apr;20(4):e208-e217. doi: 10.1016/S1470-2045(19)30084-1. Review.

PMID:
30942182
7.

"Cold turkey" or pharmacotherapy: Examination of tobacco cessation methods tried among smokers prior to developing head and neck cancer.

Khariwala SS, Rubin N, Stepanov I, Nollen N, Ahluwalia JS, Nelson HH, Hatsukami DK.

Head Neck. 2019 Jul;41(7):2332-2339. doi: 10.1002/hed.25708. Epub 2019 Feb 15.

PMID:
30770605
8.

Biomarkers of Exposure among U.S. Adult Cigar Smokers: Population Assessment of Tobacco and Health (PATH) Study Wave 1 (2013-2014).

Chang CM, Rostron BL, Chang JT, Corey CG, Kimmel HL, Sosnoff CS, Goniewicz ML, Edwards KC, Hatsukami DK, Wang Y, Del Valle-Pinero AY, Yang M, Travers MJ, Arnstein S, Taylor K, Conway K, Ambrose BK, Borek N, Hyland A, Wang L, Blount BC, van Bemmel DM.

Cancer Epidemiol Biomarkers Prev. 2019 May;28(5):943-953. doi: 10.1158/1055-9965.EPI-18-0539. Epub 2019 Feb 7.

PMID:
30733305
9.

Correlates of support for a nicotine-reduction policy in smokers with 6-week exposure to very low nicotine cigarettes.

Denlinger-Apte RL, Tidey JW, Koopmeiners JS, Hatsukami DK, Smith TT, Pacek LR, McClernon FJ, Donny EC.

Tob Control. 2019 May;28(3):352-355. doi: 10.1136/tobaccocontrol-2018-054622. Epub 2018 Nov 1.

PMID:
30385649
10.

Urine 4-(methylnitrosamino)-1-(3) pyridyl-1-butanol and cotinine in Alaska native postpartum women and neonates comparing smokers and smokeless tobacco users.

Benowitz NL, Flanagan CA, Thomas TK, Koller KR, Wolfe AW, Renner CC, Hughes C, Decker PA, Hatsukami DK, Murphy NJ, Patten C.

Int J Circumpolar Health. 2018 Dec;77(1):1528125. doi: 10.1080/22423982.2018.1528125.

11.

The Debate About Nicotine Addiction and the Role of Medicinal Products: Commentary on Zeller.

Hatsukami DK, Donny EC.

Nicotine Tob Res. 2019 Feb 18;21(3):338-339. doi: 10.1093/ntr/nty195. No abstract available.

PMID:
30312443
12.

Reducing Nicotine in Cigarettes to Minimally Addictive Levels: A New Frontier for Tobacco Control.

Hatsukami DK.

JAMA Psychiatry. 2018 Oct 1;75(10):987-988. doi: 10.1001/jamapsychiatry.2018.1829. No abstract available.

PMID:
30285225
13.

Effect of Immediate vs Gradual Reduction in Nicotine Content of Cigarettes on Biomarkers of Smoke Exposure: A Randomized Clinical Trial.

Hatsukami DK, Luo X, Jensen JA, al'Absi M, Allen SS, Carmella SG, Chen M, Cinciripini PM, Denlinger-Apte R, Drobes DJ, Koopmeiners JS, Lane T, Le CT, Leischow S, Luo K, McClernon FJ, Murphy SE, Paiano V, Robinson JD, Severson H, Sipe C, Strasser AA, Strayer LG, Tang MK, Vandrey R, Hecht SS, Benowitz NL, Donny EC.

JAMA. 2018 Sep 4;320(9):880-891. doi: 10.1001/jama.2018.11473.

14.

Tobacco biomarkers and genetic/epigenetic analysis to investigate ethnic/racial differences in lung cancer risk among smokers.

Murphy SE, Park SL, Balbo S, Haiman CA, Hatsukami DK, Patel Y, Peterson LA, Stepanov I, Stram DO, Tretyakova N, Hecht SS, Le Marchand L.

NPJ Precis Oncol. 2018 Aug 22;2:17. doi: 10.1038/s41698-018-0057-y. eCollection 2018. Review.

15.

Presence of the Carcinogen N'-Nitrosonornicotine in Saliva of E-cigarette Users.

Bustamante G, Ma B, Yakovlev G, Yershova K, Le C, Jensen J, Hatsukami DK, Stepanov I.

Chem Res Toxicol. 2018 Aug 20;31(8):731-738. doi: 10.1021/acs.chemrestox.8b00089. Epub 2018 Jul 30.

PMID:
30019582
16.

Cigarette and e-liquid demand and substitution in e-cigarette-naïve smokers.

Stein JS, Koffarnus MN, Stepanov I, Hatsukami DK, Bickel WK.

Exp Clin Psychopharmacol. 2018 Jun;26(3):233-243. doi: 10.1037/pha0000192.

17.

Patterns of Tobacco Cessation Attempts and Symptoms Experienced Among Smokers With Head and Neck Squamous Cell Carcinoma.

Khariwala SS, Hatsukami DK, Stepanov I, Rubin N, Nelson HH.

JAMA Otolaryngol Head Neck Surg. 2018 Jun 1;144(6):477-482. doi: 10.1001/jamaoto.2018.0249.

18.

Whether to push or pull? Nicotine reduction and non-combusted alternatives - Two strategies for reducing smoking and improving public health.

Smith TT, Hatsukami DK, Benowitz NL, Colby SM, McClernon FJ, Strasser AA, Tidey JW, White CM, Donny EC.

Prev Med. 2018 Dec;117:8-14. doi: 10.1016/j.ypmed.2018.03.021. Epub 2018 Mar 29.

PMID:
29604326
19.

Strong preference for mint snus flavor among research participants.

Schneller LM, Lindgren BR, Shields PG, Hatsukami DK, O'Connor RJ.

Addict Behav Rep. 2017 Jul 31;6:51-55. doi: 10.1016/j.abrep.2017.07.004. eCollection 2017 Dec.

20.

Biomarkers of Potential Harm: Summary of an FDA-Sponsored Public Workshop.

Chang CM, Cheng YC, Cho TM, Mishina EV, Del Valle-Pinero AY, van Bemmel DM, Hatsukami DK.

Nicotine Tob Res. 2019 Jan 1;21(1):3-13. doi: 10.1093/ntr/ntx273.

PMID:
29253243
21.

Effects of Filter Ventilation on Behavioral Economic Demand for Cigarettes: A Preliminary Investigation.

Stein JS, Koffarnus MN, O'Connor RJ, Hatsukami DK, Bickel WK.

Nicotine Tob Res. 2018 Sep 4;20(10):1278-1282. doi: 10.1093/ntr/ntx164.

PMID:
29065197
22.

Consortium on Methods Evaluating Tobacco: Research Tools to Inform US Food and Drug Administration Regulation of Snus.

Berman ML, Bickel WK, Harris AC, LeSage MG, O'Connor RJ, Stepanov I, Shields PG, Hatsukami DK.

Nicotine Tob Res. 2018 Sep 25;20(11):1292-1300. doi: 10.1093/ntr/ntx228.

PMID:
29059363
23.

Evaluating the utility of subjective effects measures for predicting product sampling, enrollment, and retention in a clinical trial of a smokeless tobacco product.

O'Connor RJ, Lindgren BR, Schneller LM, Shields PG, Hatsukami DK.

Addict Behav. 2018 Jan;76:95-99. doi: 10.1016/j.addbeh.2017.07.025. Epub 2017 Jul 14.

PMID:
28772248
24.

Perceived nicotine content of reduced nicotine content cigarettes is a correlate of perceived health risks.

Pacek LR, Joseph McClernon F, Denlinger-Apte RL, Mercincavage M, Strasser AA, Dermody SS, Vandrey R, Smith TT, Nardone N, Hatsukami DK, Koopmeiners JS, Kozink RV, Donny EC.

Tob Control. 2018 Jul;27(4):420-426. doi: 10.1136/tobaccocontrol-2017-053689. Epub 2017 Jul 22.

25.

High Level of Tobacco Carcinogen-Derived DNA Damage in Oral Cells Is an Independent Predictor of Oral/Head and Neck Cancer Risk in Smokers.

Khariwala SS, Ma B, Ruszczak C, Carmella SG, Lindgren B, Hatsukami DK, Hecht SS, Stepanov I.

Cancer Prev Res (Phila). 2017 Sep;10(9):507-513. doi: 10.1158/1940-6207.CAPR-17-0140. Epub 2017 Jul 5.

26.

Reducing tobacco-related harm: FDA's proposed product standard for smokeless tobacco.

Berman ML, Hatsukami DK.

Tob Control. 2018 May;27(3):352-354. doi: 10.1136/tobaccocontrol-2016-053612. Epub 2017 Jun 20.

27.

Sex differences in physiological response to the combination of stress and smoking.

Kotlyar M, Thuras P, Hatsukami DK, al'Absi M.

Int J Psychophysiol. 2017 Aug;118:27-31. doi: 10.1016/j.ijpsycho.2017.05.008. Epub 2017 May 23.

28.

Cigarette Filter Ventilation and its Relationship to Increasing Rates of Lung Adenocarcinoma.

Song MA, Benowitz NL, Berman M, Brasky TM, Cummings KM, Hatsukami DK, Marian C, O'Connor R, Rees VW, Woroszylo C, Shields PG.

J Natl Cancer Inst. 2017 Dec 1;109(12). doi: 10.1093/jnci/djx075. Review.

29.

Internalized smoking stigma in relation to quit intentions, quit attempts, and current e-cigarette use.

O'Connor RJ, Rees VW, Rivard C, Hatsukami DK, Cummings KM.

Subst Abus. 2017 Jul-Sep;38(3):330-336. doi: 10.1080/08897077.2017.1326999. Epub 2017 May 8.

30.

Cigarette Nicotine Content as a Moderator of the Relationship Between Negative Affect and Smoking.

Robinson JD, Kypriotakis G, Karam-Hage M, Green CE, Hatsukami DK, Cinciripini PM, Donny EC.

Nicotine Tob Res. 2017 Sep 1;19(9):1080-1086. doi: 10.1093/ntr/ntx068.

31.

Low Cotinine Glucuronidation Results in Higher Serum and Saliva Cotinine in African American Compared to White Smokers.

Murphy SE, Sipe CJ, Choi K, Raddatz LM, Koopmeiners JS, Donny EC, Hatsukami DK.

Cancer Epidemiol Biomarkers Prev. 2017 Jul;26(7):1093-1099. doi: 10.1158/1055-9965.EPI-16-0920. Epub 2017 Mar 6.

32.

Timing of nicotine lozenge administration to minimize trigger induced craving and withdrawal symptoms.

Kotlyar M, Lindgren BR, Vuchetich JP, Le C, Mills AM, Amiot E, Hatsukami DK.

Addict Behav. 2017 Aug;71:18-24. doi: 10.1016/j.addbeh.2017.02.018. Epub 2017 Feb 10.

33.

Biomarkers of Tobacco Exposure: Summary of an FDA-Sponsored Public Workshop.

Chang CM, Edwards SH, Arab A, Del Valle-Pinero AY, Yang L, Hatsukami DK.

Cancer Epidemiol Biomarkers Prev. 2017 Mar;26(3):291-302. doi: 10.1158/1055-9965.EPI-16-0675. Epub 2016 Nov 9.

34.

Reduced nicotine content cigarettes and use of alternative nicotine products: exploratory trial.

Hatsukami DK, Luo X, Dick L, Kangkum M, Allen SS, Murphy SE, Hecht SS, Shields PG, al'Absi M.

Addiction. 2017 Jan;112(1):156-167. doi: 10.1111/add.13603. Epub 2016 Nov 2.

35.

Impact of smoking reduced nicotine content cigarettes on sensitivity to cigarette price: further results from a multi-site clinical trial.

Smith TT, Cassidy RN, Tidey JW, Luo X, Le CT, Hatsukami DK, Donny EC.

Addiction. 2017 Feb;112(2):349-359. doi: 10.1111/add.13636. Epub 2016 Nov 28.

36.

Optimized Liquid Chromatography Nanoelectrospray-High-Resolution Tandem Mass Spectrometry Method for the Analysis of 4-Hydroxy-1-(3-pyridyl)-1-butanone-Releasing DNA Adducts in Human Oral Cells.

Ma B, Ruszczak C, Jain V, Khariwala SS, Lindgren B, Hatsukami DK, Stepanov I.

Chem Res Toxicol. 2016 Nov 21;29(11):1849-1856. Epub 2016 Oct 12.

37.

Effects of 6-Week Use of Reduced-Nicotine Content Cigarettes in Smokers With and Without Elevated Depressive Symptoms.

Tidey JW, Pacek LR, Koopmeiners JS, Vandrey R, Nardone N, Drobes DJ, Benowitz NL, Dermody SS, Lemieux A, Denlinger RL, Cassidy R, al'Absi M, Hatsukami DK, Donny EC.

Nicotine Tob Res. 2017 Jan;19(1):59-67. Epub 2016 Aug 3.

38.

Evaluation of a reduced nicotine product standard: Moderating effects of and impact on cannabis use.

Pacek LR, Vandrey R, Dermody SS, Denlinger-Apte RL, Lemieux A, Tidey JW, McClernon FJ, Bangdiwala AS, Drobes DJ, al'Absi M, Strasser AA, Koopmeiners JS, Hatsukami DK, Donny EC.

Drug Alcohol Depend. 2016 Oct 1;167:228-32. doi: 10.1016/j.drugalcdep.2016.08.620. Epub 2016 Aug 28.

39.

Application of the Smokeless Tobacco Expectancies Questionnaire to Snus.

Adkison SE, Bansal-Travers M, Rees VW, Hatsukami DK, Cummings KM, O'Connor RJ.

Am J Health Behav. 2016 Sep;40(5):652-8. doi: 10.5993/AJHB.40.5.12.

40.

Reduced nicotine content cigarettes, e-cigarettes and the cigarette end game.

Benowitz NL, Donny EC, Hatsukami DK.

Addiction. 2017 Jan;112(1):6-7. doi: 10.1111/add.13534. Epub 2016 Aug 23. No abstract available.

41.

Genetic Risk Can Be Decreased: Quitting Smoking Decreases and Delays Lung Cancer for Smokers With High and Low CHRNA5 Risk Genotypes - A Meta-Analysis.

Chen LS, Baker T, Hung RJ, Horton A, Culverhouse R, Hartz S, Saccone N, Cheng I, Deng B, Han Y, Hansen HM, Horsman J, Kim C, Rosenberger A, Aben KK, Andrew AS, Chang SC, Saum KU, Dienemann H, Hatsukami DK, Johnson EO, Pande M, Wrensch MR, McLaughlin J, Skaug V, van der Heijden EH, Wampfler J, Wenzlaff A, Woll P, Zienolddiny S, Bickeböller H, Brenner H, Duell EJ, Haugen A, Brüske I, Kiemeney LA, Lazarus P, Le Marchand L, Liu G, Mayordomo J, Risch A, Schwartz AG, Teare MD, Wu X, Wiencke JK, Yang P, Zhang ZF, Spitz MR, Amos CI, Bierut LJ.

EBioMedicine. 2016 Sep;11:219-226. doi: 10.1016/j.ebiom.2016.08.012. Epub 2016 Aug 10.

42.

Harnessing the Power of Cruciferous Vegetables: Developing a Biomarker for Brassica Vegetable Consumption Using Urinary 3,3'-Diindolylmethane.

Fujioka N, Ransom BW, Carmella SG, Upadhyaya P, Lindgren BR, Roper-Batker A, Hatsukami DK, Fritz VA, Rohwer C, Hecht SS.

Cancer Prev Res (Phila). 2016 Oct;9(10):788-793. Epub 2016 Aug 18.

43.

A review of the additive health risk of cannabis and tobacco co-use.

Meier E, Hatsukami DK.

Drug Alcohol Depend. 2016 Sep 1;166:6-12. doi: 10.1016/j.drugalcdep.2016.07.013. Epub 2016 Jul 25. Review.

PMID:
27476751
44.

Estimations and predictors of non-compliance in switchers to reduced nicotine content cigarettes.

Nardone N, Donny EC, Hatsukami DK, Koopmeiners JS, Murphy SE, Strasser AA, Tidey JW, Vandrey R, Benowitz NL.

Addiction. 2016 Dec;111(12):2208-2216. doi: 10.1111/add.13519. Epub 2016 Aug 1.

45.

The case for the WHO Advisory Note, Global Nicotine Reduction Strategy.

Hatsukami DK, Zaatari G, Donny E.

Tob Control. 2017 Mar;26(e1):e29-e30. doi: 10.1136/tobaccocontrol-2016-053134. Epub 2016 Jun 29. No abstract available.

46.

Bupropion and naltrexone for smoking cessation: A double-blind randomized placebo-controlled clinical trial.

Mooney ME, Schmitz JM, Allen S, Grabowski J, Pentel P, Oliver A, Hatsukami DK.

Clin Pharmacol Ther. 2016 Oct;100(4):344-52. doi: 10.1002/cpt.402. Epub 2016 Jun 20.

47.

Fetal Exposure to Carcinogens With Tobacco Use in Pregnancy: Phase 1 MAW Study Findings.

Flanagan CA, Koller KR, Wolfe AW, Thomas TK, Benowitz NL, Renner CC, Hughes C, Hatsukami DK, Bronars C, Murphy NJ, Day G, Decker PA, Patten CA.

Nicotine Tob Res. 2016 Nov;18(11):2162-2168. Epub 2016 May 17.

48.

Persistence and amplitude of cigarette demand in relation to quit intentions and attempts.

O'Connor RJ, Heckman BW, Adkison SE, Rees VW, Hatsukami DK, Bickel WK, Cummings KM.

Psychopharmacology (Berl). 2016 Jun;233(12):2365-71. doi: 10.1007/s00213-016-4286-x. Epub 2016 Apr 6.

49.

Nicotine and Anatabine Exposure from Very Low Nicotine Content Cigarettes.

Denlinger RL, Smith TT, Murphy SE, Koopmeiners JS, Benowitz NL, Hatsukami DK, Pacek LR, Colino C, Cwalina SN, Donny EC.

Tob Regul Sci. 2016 Apr;2(2):186-203. doi: 10.18001/TRS.2.2.9.

50.

Cognitive testing of tobacco use items for administration to patients with cancer and cancer survivors in clinical research.

Land SR, Warren GW, Crafts JL, Hatsukami DK, Ostroff JS, Willis GB, Chollette VY, Mitchell SA, Folz JN, Gulley JL, Szabo E, Brandon TH, Duffy SA, Toll BA.

Cancer. 2016 Jun 1;122(11):1728-34. doi: 10.1002/cncr.29964. Epub 2016 Mar 28.

Supplemental Content

Loading ...
Support Center